The Institute for Protein Design at the UW School of Medicine will advance medicine and improve healthcare with an initial $45 million in funding through TED’s The Audacious Project
The Institute for Protein Design will become an innovation hub for new therapeutics for a variety of common, serious diseases. It will also engineer new nanomaterials for industry.
The nanoparticle platform for this respiratory syncytial virus study will be applied to vaccine research on flu, HIV, and more. Seattle startup Icosavax will advance related clinical trials.
Interleukin-2 (IL-2) is a molecule that amps up immune cells to fight off infections. While it is effective, the problem with IL-2 is that it causes a lot of toxicity in patients.
Computationally designed protein assemblies, which display functions associated with living things, may pose ways to transport therapeutic cargos into cells without using viruses as vehicles.
